Synopsis: This document, from the Ministry of Health, Labour and Welfare of Japan, is a comprehensive Q&A collection that addresses the application of International Council for Harmonisation (ICH) guidelines to generic pharmaceuticals.
The document provides the following information:
- It emphasizes the necessity of consulting with the regulatory authority regarding various drug approval processes, most notably concerning stability testing and the submission of pertinent documentation
- The guidance clarifies the conditions under which specific requirements may be waived or modified, contingent upon particular circumstances
- In detailing the consultation process, the document suggests that consultation materials should encompass specific information to facilitate clear communication with the regulatory authority
- It explicitly states that justifiable reasons for omitting certain explanations are generally unnecessary unless significant concerns regarding stability arise
- Conditions for the omission of stability test results are articulated, ensuring that stakeholders understand when it is permissible to forgo these results
- Moreover, the document reaffirms that compliance with principles governing the analysis and validation of active ingredients is imperative
- It further advocates for seeking consultation with regulatory bodies, particularly considering the classification of biopharmaceuticals, thereby ensuring that all parties involved are aware of their obligations and the necessary steps within the framework of drug approval processes
Source
Select Mandate HA
Select Mandate Function